Trials / Not Yet Recruiting
Not Yet RecruitingNCT06438055
Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to enroll refractory breast cancer patients. Patient-derived organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for the development of personalized treatment plans.
Detailed description
Forty patients with refractory breast cancer who met the inclusion criteria were enrolled in the study after signing an informed consent form. Tumor samples were obtained through clinical puncture, and qualified samples were subjected to organoid modeling. Perform drug sensitivity test on the established breast cancer organoids. The drugs used are all that have been marketed and applied in clinical practice. According to the results of organoid drug sensitivity analysis, the patient received a treatment plan with relatively sensitive drugs. Follow up prognostic data and relevant clinical information of enrolled patients, conduct statistical analysis on the consistency between drug sensitivity test results and patient treatment response, and evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity results.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Chemotherapy and targeted-therapy guided by organoid drug sensitivity test | This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests. |
Timeline
- Start date
- 2024-06-01
- Primary completion
- 2025-06-01
- Completion
- 2026-06-01
- First posted
- 2024-05-31
- Last updated
- 2024-05-31
Source: ClinicalTrials.gov record NCT06438055. Inclusion in this directory is not an endorsement.